Effectiveness of CoronaVac and BNT162b2 covid-19 mass vaccination in Colombia: a population-based cohort study

Effectiveness of CoronaVac and BNT162b2 covid-19 mass vaccination in Colombia: a population-based cohort study

<p><strong>Background:</strong> In February 2021, Colombia began mass vaccination against COVID-19 using mainly BNT162b2 and CoronaVac vaccines. We aimed to estimate vaccine effectiveness (VE) to prevent COVID-19 symptomatic cases, hospitalization, critical care admission, and deat...

Full description

Bibliographic Details
Main Authors:	Paternina-Caicedo, A, Jit, M, Alvis-Guzmán, N, Fernández, JC, Hernández, J, Paz-Wilches, JJ, Rojas-Suarez, J, Dueñas-Castell, C, Alvis-Zakzuk, NJ, Smith, A, De La Hoz-Restrepo, F
Format:	Journal article
Language:	English
Published:	Elsevier 2022

Similar Items

Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study
by: Angel Paternina-Caicedo, et al.
Published: (2022-08-01)

Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
by: Samar Samoud, et al.
Published: (2023-08-01)

Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19
by: Dogan Mustafa, et al.
Published: (2023-06-01)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
by: Hazal Cansu Çulpan, et al.
Published: (2023-12-01)

BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVac
by: Çiğdem Erol, et al.
Published: (2023-07-01)

Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees
by: Letícia Carrijo Masson, et al.
Published: (2023-06-01)

Side Effects Related to BNT162b2 and CoronaVac Vaccine Requiring Emergency Department Visit
by: Erdal Yavuz, et al.
Published: (2022-04-01)

Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
by: Ruiqi Zhang, et al.
Published: (2022-04-01)

Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
by: Thiago Cerqueira-Silva, et al.
Published: (2022-07-01)

Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
by: Jing Lian Suah, et al.
Published: (2022-06-01)

Comparative effectiveness and safety of BNT162b2 and CoronaVac in Hong Kong: A target trial emulation
by: Eric Yuk Fai Wan, et al.
Published: (2024-09-01)

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
by: Jaime S. Rosa Duque, et al.
Published: (2022-06-01)

Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity
by: Daniel Leung, et al.
Published: (2022-09-01)

Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients
by: Michael Kwan Leung Yu, et al.
Published: (2024-12-01)

Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVac
by: Diego A. Díaz-Dinamarca, et al.
Published: (2024-08-01)

Humoral Immune Response of BNT162b2 and CoronaVac Vaccinations in Hemodialysis Patients: A Multicenter Prospective Cohort
by: Rene Clavero, et al.
Published: (2022-09-01)

Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant
by: Ka-Wa Khong, et al.
Published: (2022-01-01)

Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients
by: Ka Shing Cheung, et al.
Published: (2022-07-01)

Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey
by: Meliha Cagla Sonmezer, et al.
Published: (2022-07-01)

Author Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
by: Jaime S. Rosa Duque, et al.
Published: (2022-08-01)

Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine
by: Marcela Helena Gambim Fonseca, et al.
Published: (2022-06-01)

Myocarditis/pericarditis following vaccination with BNT162b2, CoronaVac, and ChAdOx1 among adolescent and adult in Malaysia
by: Norazida Ab Rahman, et al.
Published: (2023-08-01)

Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals
by: Nicolás A. Muena, et al.
Published: (2022-04-01)

Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study
by: Wei Kang, et al.
Published: (2022-05-01)

Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant
by: Guilherme R. F. Campos, et al.
Published: (2022-06-01)

Effect of Heterologous Vaccination Strategy on Humoral Response against COVID-19 with CoronaVac plus BNT162b2: A Prospective Cohort Study
by: Hakan Demirhindi, et al.
Published: (2022-04-01)

Humoral Immune Response to CoronaVac in Turkish Adults
by: Yasemin Cosgun, et al.
Published: (2023-01-01)

ANCA-associated vasculitis following the CoronaVac vaccination
by: Yaohui Ma, et al.
Published: (2022-11-01)

Safety and Immunogenicity of a Booster Vaccination by CoronaVac or BNT162b2 in Previously Two-Dose Inactivated Virus Vaccinated Individuals with Negative Neutralizing Antibody
by: Kristi Tsz-Wan Lai, et al.
Published: (2022-04-01)

Safety of BNT162b2 or CoronaVac COVID-19 vaccines in patients with heart failure: A self-controlled case series studyResearch in context
by: Xuxiao Ye, et al.
Published: (2023-01-01)

Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster
by: Chin Shern Lau, et al.
Published: (2022-11-01)

Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines
by: Serkan Atıcı, et al.
Published: (2023-07-01)

Effectiveness of BNT162b2 and CoronaVac in children and adolescents against SARS-CoV-2 infection during Omicron BA.2 wave in Hong Kong
by: Daniel Leung, et al.
Published: (2023-01-01)

Effectiveness of the CoronaVac® vaccine in a region of the Colombian Amazon, was herd immunity achieved?
by: Héctor Serrano-Coll, et al.
Published: (2022-01-01)

Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers
by: Gulsum Iclal Bayhan, et al.
Published: (2022-01-01)

Adverse events associated with CoronaVac in a university hospital
by: Lana N. SILVA-SANTOS, et al.
Published: (2022-12-01)

Antibody dynamics post-Comirnaty and CoronaVac vaccination in Malaysia
by: Cheng Siang Tan, et al.
Published: (2022-09-01)

Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination
by: Chua, Jia Xin, et al.
Published: (2022)

Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case–control study
by: Vincent Ka Chun Yan, et al.
Published: (2023-12-01)

Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting
by: Otávio Melo Espíndola, et al.
Published: (2023-05-01)